Published in Acta Neuropathol on July 25, 2007
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet (2010) 5.75
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol (2010) 4.48
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J (2010) 2.90
The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology (2015) 2.81
TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem (2009) 2.40
A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A (2010) 2.36
Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology (2008) 2.01
Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol (2010) 1.96
Regulated protein aggregation: stress granules and neurodegeneration. Mol Neurodegener (2012) 1.95
Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J Neurol (2009) 1.85
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet (2010) 1.81
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
The neuropathology of genetic Parkinson's disease. Mov Disord (2012) 1.73
TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol (2007) 1.73
Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet (2010) 1.56
TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol (2009) 1.56
Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol (2008) 1.53
ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol (2008) 1.49
Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem (2010) 1.47
TDP-43 in aging and Alzheimer's disease - a review. Int J Clin Exp Pathol (2011) 1.46
TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. Mamm Genome (2008) 1.44
Neurodegeneration the RNA way. Prog Neurobiol (2011) 1.43
Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology (2015) 1.42
Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol (2008) 1.31
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
TDP-43 immunoreactivity in neurodegenerative disorders: disease versus mechanism specificity. Acta Neuropathol (2007) 1.27
Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol (2009) 1.27
Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci (2009) 1.26
A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci (2013) 1.25
Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion (2011) 1.25
Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics (2011) 1.23
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol (2014) 1.21
Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3β. Protein Cell (2010) 1.19
Characterization of the Brain 26S Proteasome and its Interacting Proteins. Front Mol Neurosci (2010) 1.19
Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathol Appl Neurobiol (2010) 1.19
TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol (2010) 1.19
Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. Mol Ther (2010) 1.16
Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics (2010) 1.16
TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol (2008) 1.09
Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol (2008) 1.08
RNA processing pathways in amyotrophic lateral sclerosis. Neurogenetics (2010) 1.08
Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol (2010) 1.07
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. Acta Neuropathol (2008) 1.06
The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol (2008) 1.05
Coaggregation of RNA-binding proteins in a model of TDP-43 proteinopathy with selective RGG motif methylation and a role for RRM1 ubiquitination. PLoS One (2012) 1.05
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem (2011) 1.04
Does a loss of TDP-43 function cause neurodegeneration? Mol Neurodegener (2012) 1.02
Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. J Neuropathol Exp Neurol (2009) 1.01
The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci (2010) 1.00
Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases. Neuropathol Appl Neurobiol (2008) 0.99
Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. J Neural Transm (Vienna) (2008) 0.98
Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). J Biol Chem (2012) 0.97
Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans. Acta Neuropathol (2011) 0.97
Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. Biochem Pharmacol (2014) 0.96
TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol (2013) 0.95
On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol (2011) 0.95
TDP-43 in neurodegenerative disorders. Expert Opin Biol Ther (2008) 0.94
TAR-DNA binding protein-43 and alterations in the hippocampus. J Neural Transm (Vienna) (2011) 0.91
C9orf72 mutation is rare in Alzheimer's disease, Parkinson's disease, and essential tremor in China. Front Cell Neurosci (2013) 0.90
Recent insights into the molecular genetics of dementia. Trends Neurosci (2009) 0.90
Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Mov Disord (2009) 0.89
Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun (2015) 0.88
β-amyloid triggers ALS-associated TDP-43 pathology in AD models. Brain Res (2011) 0.88
Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J Mol Neurosci (2011) 0.87
Comparison of parallel high-throughput RNA sequencing between knockout of TDP-43 and its overexpression reveals primarily nonreciprocal and nonoverlapping gene expression changes in the central nervous system of Drosophila. G3 (Bethesda) (2012) 0.86
Astrocytic TDP-43 pathology in Alexander disease. J Neurosci (2014) 0.85
TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J Alzheimers Dis (2013) 0.85
TARDBP mutations in Parkinson's disease. Parkinsonism Relat Disord (2012) 0.85
The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet (2014) 0.85
Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathol (2014) 0.85
Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. Acta Neuropathol (2011) 0.84
TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. Acta Neuropathol (2008) 0.84
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort. Clin Exp Med Sci (2013) 0.83
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathol (2013) 0.83
Mutational analysis of TARDBP in neurodegenerative diseases. Neurobiol Aging (2009) 0.82
Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies. Int J Mol Sci (2011) 0.82
Co-occurrence of TDP-43 mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor neurons. PLoS One (2012) 0.81
Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol (2013) 0.81
Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol (2009) 0.81
TDP-43 pathology occurs infrequently in multiple system atrophy. Neuropathol Appl Neurobiol (2011) 0.81
Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin (2015) 0.80
The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. Neurogenetics (2013) 0.80
TDP-43/FUS in motor neuron disease: Complexity and challenges. Prog Neurobiol (2016) 0.79
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol Neurodegener (2015) 0.79
Anatomic and clinical pathology of cognitive impairment and dementia. J Alzheimers Dis (2013) 0.79
Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies. Neurodegener Dis (2010) 0.79
Altered Proteins in the Aging Brain. J Neuropathol Exp Neurol (2016) 0.77
Detection of TDP-43 oligomers in frontotemporal lobar degeneration-TDP. Ann Neurol (2015) 0.77
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA (2009) 8.40
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA (2005) 6.23
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science (2005) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Genomewide association studies of stroke. N Engl J Med (2009) 5.29
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med (2010) 5.27
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature (2006) 4.54
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32